German Rebate Contracts and Section 130a SGB V, Explained

German rebate contracts, known as Rabattverträge, are exclusive or non-exclusive discount agreements under section 130a paragraph 8 SGB V between a statutory health insurance fund and a pharmaceutical manufacturer. They decide which specific product a pharmacy must dispense for that fund's insured patients, so the correct answer to "which generic do I hand over" depends not on the prescription alone but on who the patient is insured with. Get it wrong and the claim is not reimbursed. This is the mechanism international market access, pricing and data teams most often underestimate about Germany, because in most countries a discount is a commercial line item rather than a dispensing instruction with the force of statute behind it.

This article is written for pharmaceutical professionals in market access, regulatory affairs, pharmacy and wholesale. It sets out what a rebate contract is, how tenders and open-house procedures differ, which product the pharmacy is obliged to dispense, how the aut-idem rule and the framework-agreement selection interact, where retax risk comes from, and how the statutory manufacturer rebates under section 130a sit alongside the contracts. It does not give legal or medical advice.

What is a German rebate contract (Rabattvertrag)?

A rebate contract is a discount agreement concluded under section 130a paragraph 8 SGB V. A statutory health insurance fund (Krankenkasse) and a manufacturer agree that the manufacturer grants the fund a rebate on a specific medicine, and in exchange that medicine becomes the preferred, often exclusive, product the fund's insured patients receive. The rebate amount itself is confidential and is not published.

The economic logic is substitution. Rebate contracts overwhelmingly cover off-patent molecules where several bioequivalent generics compete, so the fund uses the promise of dispensing volume to extract a price. Contract terms are commonly two years for tendered awards. Because each of the roughly 95 statutory funds runs its own contracts, the same active substance can map to a different preferred manufacturer depending on the patient's fund, and those mappings change every time a new award cycle closes.

Two consequences follow immediately. First, the dispensing decision is insurer-specific, not national. Second, the data that tells a pharmacy which product is under contract for which fund has to be current to the day, because a lapsed or newly awarded contract changes the obligation without any change to the clinical facts. For the broader pricing context around these contracts, see our overview of pharmaceutical pricing in Germany.

Rebate contract vs tender vs open house

"Rebate contract" is the category. Within it, the procurement route determines whether one manufacturer wins exclusivity or many suppliers join on identical terms. The distinction matters because it changes how many products satisfy the dispensing obligation at the counter.

Open-house procedures grew out of European case law that treated a simple admission model, where anyone meeting fixed terms is accepted, as sitting outside classic procurement award rules. Their defining feature is that the discount terms are identical for every company that joins, so they are non-exclusive by construction. That is why biosimilar segments, where a hard single-winner award can raise supply-security and competition concerns, frequently run through open house rather than a winner-takes-all tender.

Which product must a pharmacy dispense?

The dispensing obligation is set by section 129 SGB V and the framework agreement (Rahmenvertrag) concluded under it between the GKV-Spitzenverband and the pharmacists' representatives. The rule has a clear priority order.

1. A rebate contract exists for the patient's fund. The pharmacy must dispense the bioequivalent product covered by the section 130a(8) contract that applies to that specific fund, provided the prescriber has not blocked substitution and the product is available.
2. No rebate contract applies. The framework agreement then requires the pharmacy to select from among the most economical products, in practice one of the four cheapest available bioequivalent products in the lower price range. The statute itself does not name a fixed number, the framework agreement operationalises it.
3. Substitution is blocked or a supply exception applies. The prescribed or a clinically appropriate product is dispensed, subject to the documented exception rules.

Substitution is only permitted between products that share the same active ingredient, strength and pack-size group, are approved for at least one common indication, and have the same or an interchangeable pharmaceutical form. This is the pharmacological floor beneath the whole commercial exercise: no rebate contract can force a substitution the substitution rules do not already allow.

How aut idem and the four-cheapest rule interact

Aut idem is Latin for "or the same". On a German prescription, substitution is the default. The prescriber actively prevents it by crossing out the aut-idem field, which signals that exactly the prescribed product must be dispensed and no rebate substitution may occur. Leaving the field untouched permits substitution.

So the interaction runs as a decision cascade. If the aut-idem box is crossed, the cascade stops and the named product is dispensed. If it is not crossed, the pharmacy first looks for a rebate contract for that patient's fund and dispenses the contracted product. Only if no contract applies does the four-cheapest selection from the framework agreement come into play. A rebate contract therefore outranks the general price-based selection, and an aut-idem block outranks both. Understanding this order is essential when modelling which product a real prescription will actually resolve to, which is a different question from what was written. For the reimbursement layer that sits above generic substitution, see our note on the AMNOG reimbursement database.

Retax risk: where the money is actually lost

A retaxation, or retax, is a claim correction: the fund refuses full reimbursement for a dispensed pack, in part or in whole, after the fact. Rebate contracts are one of the largest single sources of retax exposure in German pharmacy because the dispensing obligation is data-dependent and time-sensitive.

The typical failure modes are mundane and expensive. Dispensing a therapeutically correct but non-contracted generic when a contract existed for that fund. Dispensing against a rebate mapping that lapsed the day before, or missing one that started that day. Overlooking that the patient's fund changed. Missing a documented supply-shortage exception that would have justified the substitution. None of these are clinical errors. They are reconciliation errors between the prescription, the patient's insurer and the current contract state, and they are only avoidable if the underlying status data is correct and current at the moment of dispensing. The same data-quality dependency runs through German drug reimbursement more broadly, as set out in how drug pricing works in Germany.

Statutory manufacturer rebates under section 130a

Rebate contracts under paragraph 8 are only one of several rebate mechanisms that section 130a bundles together. The others are statutory, apply by law rather than by agreement, and adjust the effective price a fund pays regardless of any contract. They are frequently confused with rebate contracts, so it is worth separating them.

The practical upshot: the statutory rebates under paragraphs 1, 3a and 3b compress the effective price on a broad, rules-based footing, while the paragraph 8 contracts add a fund-specific layer on top that also steers which product is dispensed. A pricing model that captures only the published list price and the statutory percentages will still miss the confidential contract layer that actually determines dispensing at the counter. Both layers move over time, and section 130a has been amended repeatedly, so any effective-price calculation carries a legal-status date whether it states one or not.

Where rebate and dispensing data sit in your systems

For teams integrating German drug data, the operational question is where the dispensing-relevant status lives and how current it is. pharmazie.com carries dispensing-relevant status and price context per Pharmazentralnummer (PZN), delivered through a REST API and structured data export, alongside the ABDA-Artikelstamm article master data, clinical information and daily-updated shortage data in a single consolidated search.

Two honest qualifications belong here. First, rebate-contract coverage is not asserted to be complete: the confidential, fund-by-fund contract landscape shifts with every award cycle, and no external dataset should claim to mirror it in full. Second, the article master data included is the ABDA-Artikelstamm, the manufacturer-submitted article and price registry, not any proprietary commercial Taxe used as a standalone pricing service in the retail channel. What the platform does provide is the PZN-level join key, the article and status context around it, and the cross-border reach to find equivalent products in other markets when a German product is unavailable, which is precisely the reconciliation work that rebate-driven substitution and shortage handling demand.

This content is intended for healthcare professionals and does not constitute legal, regulatory or medical advice. Legal provisions cited reflect section 130a and section 129 SGB V as published. Last reviewed: July 2026.